Inhibition of tumor growth by a newly-identified activator for epidermal fatty acid binding protein

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7815-7827

  Rao, Enyu ^a   Singh, Puja ^a   Zhai, Xiuhong ^a   Li, Yan ^a   Zhu, Ganqian ^a   Zhang, Yuwen ^a   Hao, Jiaqing ^a   Chi, Young In ^a   Brown, Rhoderick E ^a   Cleary, Margot P ^a   Li, Bing ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

E FABP; Interferon ; Tumor associated macrophages; Tumor treatment

Indexed keywords

5 [BENZYLAMINO] 2 [3 METHYLPHENYL] 1,3 OXAZOLE 4 CARBONITRILE; ANTINEOPLASTIC AGENT; BETA INTERFERON; CD86 ANTIGEN; CXCL11 CHEMOKINE; EPIDERMAL FATTY ACID BINDING PROTEIN; FAT DROPLET; FATTY ACID BINDING PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FABP5 PROTEIN, HUMAN; NITRILE; OXAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; HUMAN; MACROPHAGE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM;

ANIMALS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INTERFERON-BETA; MACROPHAGE ACTIVATION; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MODELS, MOLECULAR; NITRILES; OXAZOLES;

EID: 84928393842     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3485     Document Type: Article

References (33)

1. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
2. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46.
3. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013;38:633-43.
4. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489-503.
5. Hertzel AV, Bernlohr DA. The mammalian fatty acidbinding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000;11:175-80.
6. Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008;28:73-95.
7. Zhang Y, Li B. E-FABP: regulator of immune function. Oncoscience 2014;1:398-9.
8. Zhang Y, Sun Y, Rao E, Yan F, Li Q, Zhang Y, et al. Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-beta responses in tumor-associated macrophages. Cancer Res 2014;74:2986-98.
9. Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acidbinding protein. J Immunol 2009;182:7625-33.
10. Hertzel AV, Hellberg K, Reynolds JM, Kruse AC, Juhlmann BE, Smith AJ, et al. Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. J Med Chem 2009;52:6024-31.
11. Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S, et al. Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett 2004;14:4445-8.
12. Liu X, Huang X, Lin W, Wang D, Diao Y, Li H, et al. New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. Bioorg Med Chem Lett 2011;21:2949-52.
13. Sulsky R, Magnin DR, Huang Y, Simpkins L, Taunk P, Patel M, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett 2007;17:3511-5.
14. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959-65.
15. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739-49.
16. Sanson B, Wang T, Sun J, Wang L, Kaczocha M, Ojima I, et al. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. Acta Crystallogr D Biol Crystallogr 2014;70:290-8.
17. O'Neill LA. Immunology. Sensing the dark side of DNA. Science 2013;339:763-4.
18. Simmons DP, Wearsch PA, Canaday DH, Meyerson HJ, Liu YC, Wang Y, et al. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J Immunol 2012;188:3116-26.
19. Smyth MJ. Type I interferon and cancer immunoediting. Nat Immunol 2005;6:646-8.
20. Xie H, Lee MH, Zhu F, Reddy K, Huang Z, Kim DJ, et al. Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo. Mol Cancer Ther 2013;12:950-8.
21. Zhao W, Wang L, Zhang M, Wang P, Zhang L, Yuan C, et al. Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3-and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFNbeta promoter. J Biol Chem 2011;286:5519-28.
22. Morgan E, Kannan-Thulasiraman P, Noy N. Involvement of Fatty Acid Binding Protein 5 and PPARbeta/delta in Prostate Cancer Cell Growth. PPAR Res 2010;2010.
23. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010;207:2053-63.
24. Moschos S, Kirkwood JM. Present role and future potential of type I interferons in adjuvant therapy of highrisk operable melanoma. Cytokine Growth Factor Rev 2007;18:451-8.
25. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002;13:111-8.
26. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208:1989-2003.
27. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207:2053-63.
28. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature 2014;511:167-76.
29. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012;15:432-7.
30. Rolph MS, Young TR, Shum BO, Gorgun CZ, Schmitz-Peiffer C, Ramshaw IA, et al. Regulation of dendritic cell function and T cell priming by the fatty acid-binding protein AP2. J Immunol 2006;177:7794-801.
31. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2007;2:2212-21.
32. Zhai X, Malakhova ML, Pike HM, Benson LM, Bergen HR, III, Sugar IP, et al. Glycolipid acquisition by human glycolipid transfer protein dramatically alters intrinsic tryptophan fluorescence: insights into glycolipid binding affinity. J Biol Chem 2009;284:13620-8.
33. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007;178:1357-62.